📧 FREE CASE EVALUATION: Info@GLP1Lawsuits.com
中文
← Back to Main Page

Warnings Issued Over Compounded Semaglutide

Latest GLP-1 legal updates and medical findings.

• Pharmacy Times / FDA Safety Communication

Warnings Issued Over Compounded Semaglutide

Improper formulations, salt forms, and dosing shortcuts raise serious safety questions for weight-loss patients.

10
Reported deaths
100+
Hospitalizations
350+
Adverse events noted by FDA

Why compounded versions exist

Demand for Wegovy and Ozempic has outpaced supply, leading clinics to order custom-mixed semaglutide from outsourcing facilities.

These mixtures are not reviewed by the FDA for quality, sterility, or bioavailability.

Safety issues under investigation

Some products contain semaglutide sodium instead of the base form used in approved injections, altering potency.

Others pair semaglutide with research peptides like BPC-157, a combination the FDA explicitly prohibits.

Novo Nordisk's petition

The manufacturer asked regulators to add semaglutide to the Difficult to Compound (DDC) list, which would sharply limit pharmacy compounding.

They cited reports of dosing syringes that delivered several weeks' worth of medication at once.

Practical advice for patients

Verify that any pharmacy providing semaglutide is state-licensed and willing to show certificates of analysis.

Keep the original packaging and lot numbers in case adverse events must be reported.

Red flags to watch

  • Vials or pens shipped without manufacturer labeling
  • Sellers marketing 'bulk powder' mixed onsite
  • Clinics promising discounts without in-person lab work

Need Legal Guidance Right Now?

If you were harmed after using a compounded product, we can trace the supply chain and explore claims against both the clinic and outsourcing pharmacy.

Our intake team responds within one business day.

Start Free Case Evaluation

Find out if you have a GLP-1 claim

If you experienced serious side effects after using GLP-1 medications, you may be eligible for compensation.

Start your free case evaluation